Analyst Price Targets — IMCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 1:39 pm | — | Morgan Stanley | $43.00 | $33.26 | TheFly | Immunocore price target raised to $43 from $40 at Morgan Stanley |
| August 3, 2026 11:25 am | Graig Suvannavejh | Mizuho Securities | $35.00 | $33.81 | TheFly | Immunocore price target raised to $35 from $34 at Mizuho |
| February 19, 2026 12:17 pm | — | Mizuho Securities | $38.00 | $32.51 | TheFly | Immunocore price target raised to $38 from $37 at Mizuho |
| January 7, 2026 5:43 am | Michael Yee | UBS | $55.00 | $32.85 | StreetInsider | UBS Assumes Immunocore Holdings (IMCR) at Buy |
| November 10, 2025 5:15 pm | Sean Laaman | Morgan Stanley | $36.00 | $34.53 | TheFly | Immunocore price target raised to $36 from $34 at Morgan Stanley |
| October 31, 2025 10:16 am | Eva Fortea Verdejo | Wells Fargo | $60.00 | $32.19 | TheFly | Immunocore initiated with an Overweight at Wells Fargo |
| March 7, 2025 1:37 pm | — | Morgan Stanley | $35.00 | $29.80 | TheFly | Immunocore assumed with an Equal Weight at Morgan Stanley |
| October 24, 2024 3:51 am | David Dai | UBS | $24.00 | $32.02 | StreetInsider | UBS Starts Immunocore Holdings (IMCR) at Sell |
| September 16, 2024 10:00 am | Justin Kim | Oppenheimer | $89.00 | $33.05 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
| September 12, 2024 7:54 am | Graig Suvannavejh | Mizuho Securities | $72.00 | $33.44 | StreetInsider | Mizuho Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
Latest News for IMCR
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today…
Bank of America Corp DE trimmed its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR) by 11.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 206,866 shares of the company's stock after selling 27,871 shares during the quarter. Bank of
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMCR.
U.S. House Trading
No House trades found for IMCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.